Best Gastrointestinal Cancer Podcasts (2025)

1
Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis 50:39

Play Pause

3d ago50:39

50:39

Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. CME information and select publications here.

1
S14 Ep38: Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS 12:20

1d ago12:20

12:20

In today’s episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into …

1
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care 35:16

2d ago35:16

35:16

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including: Trials of neoadjuvant immunotherapies demonstrating remarkable response…

1
S14 Ep37: Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD 29:09

2d ago29:09

29:09

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jer…

1
S14 Ep36: Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD 26:42

3d ago26:42

26:42

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.…

1
AGA Updates Barrett's Guidelines + GLP-1 Safety Study | Oct 28 3:36

4d ago3:36

3:36

Welcome to this week's Gastroenterology and Endoscopy News Roundup, where we bring you the most important updates and research findings for gastroenterology professionals. This episode covers five critical stories from the week of October 21-28, 2025, including new clinical guidelines, groundbreaking research on procedure safety, and the latest tec…

1
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management 27:48

5d ago27:48

27:48

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes …

1
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD 15:12

5d ago15:12

15:12

In today’s episode, we had the pleasure of speaking with Armeen Mahvash, MD, about the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. Dr Mahvash is a professor in the Department of Interventional Radiology in the Division of Diagnostic Imaging at The University of Texas …

1
S14 Ep34: FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS 12:11

9d ago12:11

12:11

In today’s episode, we had the pleasure of speaking with Vishal A. Patel, MD, FAAD, FACMS, about the FDA approval of adjuvant cemiplimab-rwlc (Libtayo) for the treatment of patients with high-risk cutaneous squamous cell carcinoma (CSCC). Dr Patel is an associate professor of dermatology at the GW School of Medicine & Health Sciences, as well as th…

1
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum 32:50

10d ago32:50

32:50

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.By OncLive® On Air

1
S14 Ep32: Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD 13:26

11d ago13:26

13:26

In today’s episode, we had the pleasure of speaking with Eunice Wang, MD, about the secondary AML treatment paradigm. Dr Wang is a professor of oncology, leader of the Leukemia Clinical Disease Team, chief of leukemia in the Department of Medicine, and an assistant member of the Tumor Immunology Program in the Department of Immunology at Roswell Pa…

1
S14 Ep31: Metastatic Breast Cancer 2025 UPDATE 11:41

13d ago11:41

11:41

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
S14 Ep30: FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP 4:36

17d ago4:36

4:36

In today’s episode, we had the pleasure of speaking with J. Thaddeus Beck, MD, FACP, about the FDA approval of pembrolizumab and berahyaluronidase alfa-pmph (subcutaneous pembrolizumab; Keytruda Qlex) for subcutaneous injection in adult and pediatric patients at least 12 years of age with solid tumors for which the intravenous formulation of pembro…

1
S14 Ep29: Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD 38:01

17d ago38:01

38:01

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will sit down …

1
Ep 6 - Inside AECs: Where ‘Skin in the Game’ Meets Innovation, Access, and the Ability to Adapt 47:14

19d ago47:14

47:14

See how ambulatory endoscopy centers (AECs) are reshaping GI care—combining independent physicians’ personal investment with “nimble” innovation and improved patient access. In this episode, Olympus’ Director of Strategic Marketing for GI Diane Locher, joins Dr. Nalini Guda of GI Associates and Dr. Neil Parikh of CTGI & GI Alliance to discuss the u…

1
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer 26:10

19d ago26:10

26:10

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on h…

1
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer 23:57

19d ago23:57

23:57

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare pro…

1
S14 Ep28: Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress 13:27

20d ago13:27

13:27

In today’s episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress. Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT0540355…

1
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options 37:10

20d ago37:10

37:10

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including: Brief overview of BTC and GEA Approved HER2-directed therapies for BTC and GEA and their mechanisms of acti…

1
S14 Ep27: FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR 11:55

23d ago11:55

11:55

In today’s episode, we had the pleasure of speaking with Joseph Jacob, MD, MCR, about the FDA approval of the gemcitabine intravesical system (formerly TAR-200; Inlexzo) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer. Dr Jacob is an associate professor of urology and the director of Urologic Oncology in the …

1
S14 Ep26: FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD 5:43

25d ago5:43

5:43

In today’s episode, we had the pleasure of speaking with Lyudmila Bazhenova, MD, about the FDA approval of sunvozertinib (Zegfrovy) for patients with EGFR-mutated metastatic non–small cell lung cancer (NSCLC). Dr Bazhenova is a clinical professor of medicine at the University of California San Diego (UCSD); as well as a medical oncologist at the UC…

1
S14 Ep25: Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD 9:26

27d ago9:26

9:26

By OncLive® On Air

1
ENDURO Trial Results, EASL Hepatitis B Guidelines 2025, AI in Endoscopy & IBS Biomarkers | Latest GI Updates 13:57

27d ago13:57

13:57

By Gastroenterology and Endoscopy

1
S14 Ep24: FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD 12:45

1M ago12:45

12:45

In today’s episode, we had the pleasure of speaking with Anne Chiang, MD, PhD, and Stephen Liu, MD, about the FDA approval of lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose diseas…

1
S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD 9:48

1M ago9:48

9:48

In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Dev…

1
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD 11:11

1M ago11:11

11:11

In today’s episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida. In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with m…

1
S14 Ep21: Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD 8:48

1M ago8:48

8:48

In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing re…

1
S14 Ep20: The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD 16:19

1M ago16:19

16:19

In today’s episode, we had the pleasure of speaking with Asad Dean, MD, about treatment selection for patients with chronic lymphocytic leukemia (CLL) in the second-line setting. Dr Dean is a physician at the Texas Oncology-Fort Worth Cancer Center. In our exclusive interview, Dr Dean discussed the roles of covalent BTK inhibitors and BCL-2 inhibit…

1
Guideline Glow-Up: IBD Updates, AI Insights, and UC Breakthroughs in Gastro 7:30

1M ago7:30

7:30

In this quick-hit episode, we cover the freshest guidelines reshaping IBD, colorectal surveillance, gastric premalignancy, and gastroparesis management. Dive into cutting-edge research on AI for efficiency, targeted therapies, H. pylori strategies, advanced endoscopy, and cost-saving insights. Plus, spotlight on new tech warnings, bariatric devices…

1
Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management 44:34

1M ago44:34

44:34

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

1
S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD 8:28

1M ago8:28

8:28

In today’s episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Cen…

1
S14 Ep18: Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD 16:13

2M ago16:13

16:13

In our exclusive interview, Dr Chase discussed the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies. For first recurrences, she explained that carboplatin and paclitaxel with pembrolizumab (Keytruda) or dostarlimab-gxly (Jemperli) is recommended for patients with mismatch repair–def…

1
S14 Ep17: Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC 18:28

2M ago18:28

18:28

In this podcast, experts Aditya Bardia, MD, MPH, FASCO, Erika P. Hamilton, MD, and Virginia Kaklamani, MD, DSc, discuss frequently asked questions regarding the use of antibody-drug conjugates (ADCs) in triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC 18:30

2M ago18:30

18:30

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep15: Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD 7:02

2M ago7:02

7:02

In today’s episode, we had the pleasure of speaking with Evelyn Y. Wong, MD, about the growing challenge of early-onset colorectal cancer (CRC) and the insights from a recent cohort analysis conducted in Singapore. Dr Wong is a consultant medical oncologist specializing in gastrointestinal cancers at the National Cancer Centre Singapore. In our exc…

1
S14 Ep14: Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC 18:17

2M ago18:17

18:17

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; and Tiffany A. Traina, MD, FASCO; discuss navigating between currently available therapies for patients with triple-negative breast cancer (TNBC). They also discuss the potential ramifications of ongoing clinical trials on future treatment paradigms.…

1
S14 Ep13: Dissecting Clinical Trial and Real-World Data for ADCs in TNBC 20:08

2M ago20:08

20:08

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC 17:00

2M ago17:00

17:00

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC 14:48

2M ago14:48

14:48

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss unmet needs in triple-negative breast cancer (TNBC) and the rationale for using TROP2-targeting antibody-drug conjugates (ADCs) in this disease.By OncLive® On Air

1
S14 Ep10: Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes 15:30

2M ago15:30

15:30

In today’s episode, we had the pleasure of speaking with John N. Allan, MD, and Melissa Rubianes about factors that influence treatment decision-making in chronic lymphocytic leukemia (CLL). Allan is an associate professor of clinical medicine and a member of the lymphoma faculty in the Division of Hematology and Medical Oncology, as well as a memb…

1
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma 22:53

2M ago22:53

22:53

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the …

1
Game Changers: TL1A Inhibitors Transform IBD Care, New Pregnancy Guidelines, and the Blood Test Revolution in CRC Screening 8:44

2M ago8:44

8:44

This week's episode is packed with breakthrough developments that could reshape gastroenterology practice. We dive deep into the potentially transformative TL1A inhibitors showing remarkable results in IBD, explore the first-ever global consensus guidelines for managing IBD during pregnancy, and discuss how a simple blood test is revolutionizing co…

1
S14 Ep9: Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS 13:37

2M ago13:37

13:37

In today’s episode, we had the pleasure of speaking with Balazs Halmos, MD, MS, about the phase 2 VISION trial (NCT02864992) evaluating tepotinib (Tepmetko) in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer (NSCLC). Dr Halmos is a professor in the Department of Oncology (Medical Oncology) and the Department of Medic…

1
S14 Ep8: Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD 21:10

2M ago21:10

21:10

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
S14 Ep7: Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS 15:30

2M ago15:30

15:30

In today’s episode, we passed the mic to Tara E. Seery, MD, who moderated an OncLive Insights discussion on the future of the pancreatic cancer treatment paradigm. Rounding out the discussion with additional expert perspectives were Paul E. Oberstein, MD, and Priyadarshini Pathak, MBBS. Seery is a medical oncologist at the Hoag Family Cancer Instit…

1
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients 13:57

2M ago13:57

13:57

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including: How patients often present with disease-related symptoms Treatment selection considerations for the first-line and second-line setting How to approach palliative care discussions with pa…

1
S14 Ep6: Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP 21:38

2M ago21:38

21:38

In today’s episode, we spoke with Scott Kopetz, MD, PhD, FACP, about the use of circulating tumor DNA (ctDNA) in patients with colorectal cancer (CRC). Dr Kopetz is the deputy chair for Translational Research and a professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine, as well as the leader of the …

1
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma 16:48

2M ago16:48

16:48

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently u…

1
S14 Ep5: Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD 15:03

2M ago15:03

15:03

In today’s episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California.…

1
Ep 5 - Pinpointing GI Bleeds: Olympus Experts Talk Hemostasis and Imaging Innovation 28:36

2M ago28:36

28:36

When a GI bleed strikes, the atmosphere in the procedure room changes instantly. In this episode of OlympusTalks, Olympus’ Christian Stroupe and Robert Barrett share how Olympus® technologies are designed to help physicians regain visibility and respond quickly to find the bleed and achieve hemostasis. Chapter 1: Meet the Guests Olympus’ Christian …